Followers | 4048 |
Posts | 152449 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Friday, January 05, 2024 11:35:09 AM
please tell us LL
Recent ATXI News
- Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit • GlobeNewswire Inc. • 10/09/2024 12:30:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 08:18:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 08:55:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 08:55:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 08:53:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 08:53:10 PM
- Avenue Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 09/03/2024 12:30:35 PM
- Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 08/13/2024 08:05:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:16:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:13:12 PM
- Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 08/09/2024 08:05:01 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/12/2024 08:09:03 PM
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 12:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:30:20 PM
- Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) • GlobeNewswire Inc. • 05/16/2024 12:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:01:25 PM
- Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 05/15/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/13/2024 04:15:21 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/10/2024 08:53:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 08:52:35 PM
- Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds • GlobeNewswire Inc. • 04/29/2024 12:00:14 PM
- Avenue Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/24/2024 11:30:41 AM
- Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 • GlobeNewswire Inc. • 03/25/2024 12:30:00 PM
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/18/2024 08:05:14 PM
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq • GlobeNewswire Inc. • 03/15/2024 12:15:01 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM